



Detection of the *tst* gene and determining the relationship between the presence of the *mecA* gene and antibiotic resistance of *Staphylococcus aureus* Isolated from some Hospital in Dhi Qar province

Mushtaq Talib Al-Safi¹

¹Ministry of Education, General Directorate of Education in Thi-Qar, Iraq

*Corresponding author: Mushtaq Talib Al-Safi, Ministry of Education, General Directorate of Education in Thi-Qar, Iraq, Email: mushtaq.alsafi.@utq.edu.iq

Submitted: 11 January 2023; Accepted: 13 February 2023; Published: 15 March 2023

ABSTRACT

Methicillin, a β -lactam antibiotic, acts by inhibiting penicillin-binding proteins (PBPs) that are involved in the synthesis of peptidoglycan, an essential mesh-like polymer that surrounds the cell. *S. aureus* can become resistant to methicillin and other β -lactam antibiotics through the expression of a foreign PBP, PBP2a, that is resistant to the action of methicillin but which can perform the functions of the host PBPs. Methicillin-resistant *S. aureus* isolates are often resistant to other.

Out of 163 samples, 44 (26.99%) isolates of staphylococcus bacteria were diagnosed. Ten antibiotics were tested, where the bacteria showed the highest resistance of 100% to cefalexin and cefuroxime, and it was sensitive to Erythromycin with a percentage of (52.27%). It was also noted that the percentage of the *mecA* gene was (41)93.18% in the study samples and the percentage of the *tst* gene (14) was 31.81%.

Keywords: *Staphylococcus aureus* , , *virulence gene* , *antibiotic-resistance property*

INTRODUCTION

Staphylococcus aureus is considered an opportunistic pathogenic bacterium due to its ability to take advantage of damaged cutaneous layers. It can cause infections ranging from mild skin irritation or a simple rash to severe illness including Toxic Shock Syndrome, abscesses, bone infections, and sepsis. These bacteria are capable of wreaking havoc within the human body, primarily by destroying red blood cells through the production of hemolytic toxins and causing sudden drops in blood pressure that can result in death. *S. aureus* is the primary cause of lower respiratory tract and surgical site infections and is the second leading cause of bacteremia, pneumonia, and cardiovascular infections [1].

Methicillin resistant *S. aureus* (MRSA) has become a major public health problem all over the world. It is correlated with incremented morbidity and mortality, compared to other pathogenic bacteria. The elevated colonization rates lead to the incrimination of infection rates in the community and medical centers which leads to a significant increase in treatment cost [2].

The majority of researches in this field suggested that *mecA* gene that is present in all MRSA strains and is known to encode penicillin binding protein 2a (PBP2a), which has a low tropism to all β -lactam antibiotics, is the corner stone responsible for producing MRSA phenomenon [3,4]. Beta-lactam resistance is attributed mostly to mutations in the *mecA* gene, but other genetic elements may also be considered for the explanation of the mechanism of resistance [5]. Molecular amplification of the *mecA* gene is recognized as a benchmark to diagnose MRSA in the community as these genes are highly conserved among staphylococcal species [6].

percentage of strains of MRSA is relatively high in Asia, such as 60% in Taiwan reached, 20% in China, 70% in Hong Kong, 5% in Philippines, and 60% in Singapore. In Indonesia in 2006, MRSA prevalence is 23.5% [7]. A study in Dr. Soetomo Hospital, Surabaya showed that of 643 patients there were 52 MRSA (8%) [8]. In contrary, a study in Central Public Hospital Haji Adam Malik Medan showed quite higher prevalence of MRSA, in which in January-June 2015 there were 56 isolates (67%), in July-December 2015 there were 48 isolates (57%), and January-June 2016, 58 isolates (45%) were MRSA. Genotypes examination for MRSA

resistance has been conducted to know antibiotics resistance gene such as *mecA* [9]. The gold standard to determine MRSA genotypes is to detect conserved genes (fixed/ preserved) constantly found in *mecA* gene, which is within range of a particular chromosome in Staphylococcal Cassette Chromosome (SCCmec) [10]. MRSA resistance is due to the mutant protein of penicillin-binding protein 2a (PBP2a or PBP2') encoded by *mecA* gene. PBP is a group of enzymes in the cell membrane of *S. aureus* that catalyzes the trans-peptidation for peptidoglycan chain (crosslinkage) formation. The affinity of PBP2a is so low that MRSA stays alive in high concentration of antimicrobial exposure [11]. Amplification of *mecA* can be done by using polymerase chain reaction (PCR), which is the gold standard for the detection of *mecA* [12].

Staphylococcus aureus produces a wide variety of exoproteins that contribute to its pathogenicity. However, only a small number of its isolates produce additional exoproteins, such as Toxic Shock Syndrome Toxin (TSST), which belongs to pyrogenic toxin superantigens (PTSAgs) [13]. Furthermore TSST is a protein with 22-kD molecular weight, which is encoded by the *tst* gene [14]. This protein affects cells of the immune system and stimulates release of interleukin-1, interleukin-2, tumor necrosis factor-alpha

(TNF- α) and nonspecific T cell proliferation, which may lead to a severe and potentially fatal disease in humans, known as toxic shock syndrome (TSS) [15,16].

MATERIALS AND METHODS

Culturing and identification

163 samples were collected from various hospitals and medical centers at Nasiriyah City, southern Iraq. Clinical samples were collected for the period December 2021 to February 2022. *Staphylococcus* grows easily on most routine media at aerobic or micro-aerophilic conditions. It quickly grows at (37°C), and the ideal temperature in which the pigment is formed is 20-25°C. *S. aureus* usually forms grey to golden yellow colonies due to carotenoids. Produces α -haemolysis on horse, sheep or human blood agar plates [17,18]. The bacterial morphology was observed microscopically as Gram-positive cocci arranged in grape-like irregular clusters [18]. All

S. aureus strains produce coagulase enzyme. *S. aureus* are catalase positive and oxidase negative 17. *S. aureus* express a clumping factor (fibrinogen affinity factor) 19. *Staphylococcus* can grow in a medium with a high salt concentration, so they can grow easily in MSA. The acidity of the medium changes as the bacteria ferments mannitol and turn phenol red pH-indicator; *S. aureus* changes color of MSA from the alkaline (red) to the acidic (yellow), while the rest of the *Staphylococcus* will grow without changing the color of the medium 18.

Antibiotic Susceptibility Testing

Susceptibility test was done for all the 44 *S. aureus* isolates against the following antibiotics: Amoxicillin, Cefalexin, Cefazolin, Cefuroxime, Ciprofloxacin, Erythromycin, Gentamycin, Levofloxacin, Vancomycin, and Moxifloxacin E (HiMedia) by modified Kirby-Bauer technique based on NCCLS regulations 20,21. Furthermore, E-test was used to estimate the minimum inhibitory concentrations (MICs) for all MRSA isolates as instructed by the manufacturer.

DNA isolation

MRSA was sub-cultured on blood agar and incubated at 37°C for 18-24 hours. The cell was broken by a freeze-thaw method 22. The freeze-thawed solution was spin at 13,000 rpm for 5 minutes. The supernatant was separated from cell debris, and subjected to DNA purification check.

Amplification of mecA Gene

S. aureus strains were subjected to PCR searching for the *mecA* gene according to Al-Abbas 2012 23. PCR protocol was adopted in 25 µL volume which contains 1U Taq polymerase and the buffer conditions recommended by the manufacturer (Promega). A PCR program was conducted with initial denaturation at 94°C for 5min followed by 30 cycles of 94°C for 60sec, 62°C for 30 sec, and 72°C for 35 sec ended with

a final extension at 72°C for 10 min. Then, the PCR product was visualized under UV transilluminator on 2% agarose, and the following primers were used Forward: AAA ATC GAT GGT AAA GGT TGG C and Reverse: AGT TCT GCA GTA CCG GAT TTT C. These produce a PCR amplicon of 532 base pairs.

PCR for Detection of Virulence Genes *tst* in *Staph. aureus*

For PCR amplification, the reaction mixture (30 µL) contained 1 µL of primer F (10 pmol/µL), 1 µL of primer R (10 pmol/µL), 0.6 µL of deoxynucleoside triphosphate (10 mmol/L) 24, 3 µL of 10× PCR buffer 25, 1.8 µL of MgCl₂ (25 mmol/L) 26, 0.1 µL of Taq DNA polymerase (5 U/µL) 27, and 20 µL of distilled water. Finally, 2.5 µL of DNA preparation was added to each 0.2-mL reaction tube. The tubes were subjected to thermal cycling 28. A PCR program was conducted with initial denaturation at 94°C for 5min followed by 30 cycles (94°C, 2 min; 55°C, 2 min; 72°C, 1 min) ended with a final extension at 72°C for 5 min. the PCR product was visualized under UV transilluminator on 2% agarose, and the following primers were used Forward: ATG GCA GCA TCA GCT TGA TA and Reverse: TTT CCA ATA ACC ACC CGT TT. These produce a PCR amplicon of 350 base pairs.

RESULTS

A total of 163 samples were collected from various hospitals and medical centers at Nasiriyah City, for the period December 2021 to February 2022 and examined for detection of *S. aureus* bacteria. Only 44/163 (26.99%) samples have been gave growth for staph aureus, Phenotype test of antimicrobial agents showed that most isolates were resistant. The percentage for antimicrobial sensitivity can be seen in Table below.

TABLE 1. Percentages of antimicrobial resistance of *S.aureus* against 10 types of antimicrobial agents according to CLSI 2014 (n= 44).

Antibiotic susceptibility			
Antimicrobial Agents	Resistant N (%)	Intermediate N (%)	Sensitive N (%)
Amoxicillin	43 (97.72)	0 (0)	1 (2.27)
Cefalexin	44 (100)	0 (0)	0 (0)
Cefazolin	42 (95.45)	1 (2.27)	1 (2.27)
Cefuroxime	44 (100)	0 (0)	0 (0)
Ciprofloxacin	43 (97.72)	0 (0)	1 (2.27)
Erythromycin	20 (45.45)	1 (2.27)	23 (52.27)
Gentamycin	38 (86.36)	1 (2.27)	5 (11.36)
Levofloxacin	43 (97.72)	0 (0)	1 (2.27)
Moxifloxacin	41 (93.18)	0 (0)	3 (6.81)
Vancomycin	33 (75)	3 (6.81)	8 (18.18)

Molecular detection

The current study, through molecular detection, showed that the *mecA* gene was found in 93.18%

while the *tst* gene was found in 31.81%, of the samples under study, as shown in the table below.

TABLE 2. The percentage of the presence of the gene in the research samples

Gen (n = 44)	Present %	Absent %	total
<i>mecA</i>	41 (93.18)	3 (6.81) %	44(100%)
<i>tst</i>	14 (31.81)%	30 (68.18) %	44(100%)




FIGURE 1. Electrophoresis of genomic DNA on agarose gel 0.8% . (M) DNA marker (100 bp ladder). Lane (1- 9) No. of genomic DNA of *S.aureus*




FIGURE 2. PCR amplified products of *mecA* Gene of the *Stap. aureus* using the designed primers with expected size 532bp. (M) DNA marker (100bp ladder). Lane (1-12) No. of amplify of *mecA* gene in isolates of *S. aureus*




FIGURE 3. PCR amplified products of *tst* Gene of the *Stap. aureus* using the designed primers with expected size 350bp. (M) DNA marker (100bp ladder). Lane (2,3,4,5,7) positively amplified *mecA* and (1,6) *tst* negative in isolates of *S. aureus*

DISCUSSION

The current study, through molecular detection, showed that the *mecA* gene was found in 93.18%.

Data from Clinical and Laboratory Standards Institute (CLSI) 2015 showed that isolates resisted to cefoxitin were also resistant to 52 other types of antibiotics. Cefoxitin including second generation Cephalosporin is a potent inducer of *mecA* regulatory system that is used extensively as a marker for the detection of the *mecA* gene 29.

In this study high resistant was showed to cefalexin and cefuroxime (100 %), amoxicillin , levofloxacin and ciprofloxacin

(97.72%), cefazolin (95.45%), moxifloxacin (93.18 %) gentamycin(86.36%). In contrary, the isolates were still sensitive to vancomycin (75%) and erythromycin (52.27%). For antibiotics treatment, these antibiotics may still be used.

Another study in Indonesia showed similar pattern of antibiotic resistant in which *S. aureus* of clinical samples was resistant not only to penicillin and methicillin, but also resistant to tetracycline (24.55%), oxacillin (2.1%), gentamicin (1.1%), erythromycin (5.11%), chloramphenicol (9.22%), and trimethoprim/sulfamethoxazole (7.11%) 30. However, the percentage of isolates resistant to

other antibiotics was relatively lower compared to that of this study. Al Ruaily and Khalil (2011) study in Saudi Arabia showed *S. aureus* isolates were resistance to cephalosporins (95%), gentamycin (95%), ciprofloxacin (87%), vancomycin (100%), and penicillin (100%) 31.

A similar study of Elhassan et al. isolated from different clinical specimens in Shendi City, Sudan showed that all isolates of *S. aureus* were resistance to methicillin, penicillin, and ampicillin 32. Resistant to gentamycin, ciprofloxacin, and clindamycin were showed in 80% of the isolates, while resistant to trimethoprim/sulfamethoxazole was showed in 74% of the isolates. Sudigdoadi (2010) showed that 89% of his isolates were resistant to gentamycin 33. question may develop the ability to destroy the antibiotic or to grow in its.

Beta-lactam antibiotics kill bacteria by inhibiting cell wall synthesis. MRSA resistance to betalactam group is due to a protein mutant of penicillin-binding protein 2a (PBP2a or PBP 2') encoded in *mecA* gene. PBP is a group of enzymes in the cell membrane of *S. aureus* that catalyzes the transpeptidation for the formation of peptidoglycan chain webbing (cross-linkage). Affinity PBP2a antimicrobial beta-lactam group is so low that MRSA remains alive in a high concentration of antimicrobial exposure 34.

It was interesting that the isolates showed resistant to vancomycin. The resistant to vancomycin (VRSA) is associated with changing and resetting bacterial cell wall.

In addition, overproduction of Penicillin Binding Protein-2 (PBP-2) is also considered as an important factor for the expression of resistance to vancomycin. It is known that resistance to vancomycin is mediated by specific gene *vanA* to glycopeptides 35. Vancomycin resistant isolates is likely due to spontaneous mutations, occur acquisition of resistant factors from elsewhere, or from the surrounding enteric bacterial population 36.

Through molecular detection, showed that the *tst* gene was found in 31.81%, of the samples under study.

Different numbers of *tst*-positive *S. aureus* have been reported in previous studies. Using the PCR method, El- Ghodban et al. recorded that only 3 out of 40 *S. aureus* isolated from clinical sources

possessed the *tst* gene 37. Mehrotra et al. examined 107 *S. aureus* isolated from healthy carriers to determine *tst* positive samples and showed that 24.3% possessed this gene 10. Also many studies have been conducted on the presence of *tst* gene in *S. aureus* isolates from Iran. Kord and Amini analyzed 76 *S. aureus* strains isolated from clinical samples. Their results showed that only 8.95% of isolates were positive for the *tst* gene 38. In another study, performed on 100 MRSA and 100 MSSA isolates in Hamadan, the prevalence of TSST-1 was 11% 39.

S. aureus produces a wide variety of exotoxins, among the numerous toxins of including enterotoxins, the enterotoxins super antigens have already been assigned to the pyrogenic toxin super antigen family based on their biological activity and structural similarity, toxic shock toxin-1 (TSST-1) that induces super antigenic activity, and exfoliative toxins (ETs), these toxins are responsible for specific acute clinical syndromes such as toxic shock syndromes (TSS), food poisoning due to staphylococcus enterotoxins and staphylococcal scarlet fever (a mild form of TSS), all these toxins share in their structural and biological properties, and this indicates that they are derived from a common ancestor. 40. Another class of genetic characteristics of staphylococci is a super-antigen that encoded by *tst* gene, that carried on mobile genetic elements (MGE) named (SaPIs.), nearly 15 kb genomic regions that significantly denote a number of virulence genes, (SaPIs) linked to specific *S. aureus* genetic families, known as lineages 41-46. Toxic shock syndrome-1 (TSS-1) Secondary inflammatory complications include invasive forms of bacterial diseases Such as inflammation of the lungs, lung abscesses, urinary tract infections, food poisoning, osteoarthritis, Endocarditis, meningitis, arthritis, toxic shock syndrome, septicemia, Death 47-50.

REFERENCE

1. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of *Staphylococcus aureus* nasal colonization in the United States, 2001–2002. *J Infect Dis.* 2006;193(2):172-179. doi:10.1086/499632.
2. C. Liu, C. J. Graber, M. Karr et al., “A population-based study of the incidence and molecular epidemiology of methicillin-resistant *Staphylococcus aureus* disease in San Francisco,

- 2004- 2005,” *Clinical Infectious Diseases*. 2008; vol. 46, no. 11, pp. 1637–1646.
3. K. Ubukata, R. Nonoguchi, M. Matsushashi, and M. Konno, “Expression and inducibility in *Staphylococcus aureus* of the *mecA* gene, which encodes a methicillin-resistant *S. aureus* specific penicillin-binding protein,” *Journal of Bacteriology*. 1989; vol. 171, no. 5, pp. 2882–2885.
4. B. Berger-Bachi, “Genetic basis of methicillin resistance in *Staphylococcus aureus*,” *Cellular and Molecular Life Sciences*. 1999; vol. 56, no. 9-10, pp. 764–770.
5. M. Matsushashi, M. D. Song, F. Ishino et al., “Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to β -lactam antibiotics in *Staphylococcus aureus*,” *Journal of Bacteriology*. 1986; vol. 167, no. 3, pp. 975–980.
6. M. A. Al-Abbas, “Antimicrobial susceptibility of *Enterococcus faecalis* and a novel *Planomicrobium* isolate of bacteremia,” *International Journal of Medicine and Medical Sciences*. 2012 ; vol. 4, no. 2, pp. 19–27.
7. Sulistyarningsih. Uji kepekaan beberapa sediaan antiseptik Terhadap bakteri *Staphylococcus aureus* dan *Staphylococcus aureus* resisten metisilin (MRSA) [Tesis]. Bandung : Universitas Padjajaran, 2010.
8. Kuntaman K, Hadi U, Setiawan F, Koendori EB, Rusli M, Santosaningsih D, Severin J, and Verbrugh HA . Prevalence of Methicillin-Resistant *Staphylococcus aureus* from nose and throat of patients on admission to medical wards of Dr. Soetomo Hospital, Surabaya, Indonesia. *Southeast Asian J Trop Med Public Health*. 2016; 47(1) : 1 – 5
9. Sjahrurachman A. Cara Genetis untuk Menentukan Kepekaan Bakteri terhadap Antibiotik. CDK. 2011; Vol. 38(7) : 498 – 502.
10. Jain A, Agarwal A, and Verma RK. Cefoxitin disc diffusion test for detection of methicillin-resistant staphylococci. *Journal of Medical Microbiology*. 2008; 57: 957–961.
11. Felten A, Grandry B, Lagrange PH, and Casin I. Evaluation of three techniques for detection of low- level Methicillin-Resistant *Staphylococcus aureus* (MRSA): a disk diffusion method with cefoxitin and moxalactam, the vitek 2 system, and the MRSA – screen latex agglutination test. *Journal of Clinical Microbiology*. 2002;40 (8) : 2766 – 2771.
12. Jonas D, Speck M, Daschner FD and Grundmann H. Rapid PCR Based Identification of Methicillin-Resistant *Staphylococcus aureus* from Screening Swabs. *J Clin Microbiol*. 2002; 40: 1821-1823.
13. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. *Science*. 1990;248(4956):705–11. [PubMed: 2185544].
14. Ruzin A, Lindsay J, Novick RP. Molecular genetics of SaPII—a mobile pathogenicity island in *Staphylococcus aureus*. *Mol Microbiol*. 2001;41(2):365–77. [PubMed: 11489124].
15. Ikejima T, Okusawa S, van der Meer JW, Dinarello CA. Induction by toxic-shock-syndrome toxin-1 of a circulating tumor necrosis factorlike substance in rabbits and of immunoreactive tumor necrosis factor and interleukin-1 from human mononuclear cells. *J Infect Dis*. 1988;158(5):1017–25. [PubMed: 3263446].
16. Crass BA, Bergdoll MS. Toxin involvement in toxic shock syndrome. *J Infect Dis*. 1986;153(5):918–26. [PubMed: 3701106].
17. Suzuki, Haruo, Tristan Lefébure, Paulina P. Bitar, and Michael J. Stanhope. “Comparative Genomic Analysis of the Genus *Staphylococcus* Including *Staphylococcus Aureus* and Its Newly Described Sister Species *Staphylococcus Simiae*.” *BMC Genomics*. 2012; 13(1).
18. Gillet, Yves, Bertrand Issartel, Philippe Vanhems, Jean Christophe Fournet, Gerard Lina, Michèle Bes, François Vandenesch, Yves Piémont, Nicole Brousse, Daniel Floret, and Jerome Etienne. “Association between *Staphylococcus Aureus* Strains Carrying Gene for Panton-Valentine Leukocidin and Highly Lethal Necrotising Pneumonia in Young Immunocompetent Patients.” *Lancet* . 2002; 359(9308):753–59.
19. Reddy, Prakash Narayana, Krupanidhi Srirama, and Vijaya R. Dirisala. “ An Update on Clinical Burden, Diagnostic Tools, and Therapeutic Options of *Staphylococcus Aureus* .” *Infectious Diseases: Research and Treatment*. 2017; 10:117991611770399.
20. J. G. Collee, A.G. Fraser, B. P. Marmion, and A. Simmons, Eds., Mackie & McCartney *Practical Medical Microbiology*, Churchill Livingstone, New York, NY, USA, 14th edition, 1996.
21. National Committee for Clinical Laboratory Standards, *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically*, Approved Standard M7-A2, National Committee for Clinical Laboratory Standards, Villanova, Pa, USA, 2nd edition, 1990.
22. Bennimath VD, Gavimath CC, Kalburgi PB, and Kelmani C. Amplification and sequencing of *mecA* gene from Methicillin Resistant *Staphylococcus aureus*. *International Journal of Advanced Biotechnology and Research*. 2011; 2(3): 310-314.
23. M. A. Al-Abbas, “Antimicrobial susceptibility of *Enterococcus faecalis* and a novel *Planomicrobium* isolate of bacteremia,” *International Journal of Medicine and Medical Sciences*. 2012; vol. 4, no. 2, pp. 19–27.

24. Anand KB, Agrawal P, Kumar S, and Kapila K. Comparison of cefoxitin disc diffusion test, oxacillin screen agar, and PCR for *mecA* gene detection of MRSA. *Indian Journal of Medical Microbiology*. 2009; 27(1) : 27-29.
25. Lestari ES, dan Severin JA. *Antimicrobial Resistance in Indonesia (Prevalence, determinants, and genetic basis)*. Rotterdam: Erasmus University, 2009.
26. Al - Ruaily MA, and Khalil OM. Detection of (*mecA*) gene in Methicillin Resistant *Staphylococcus aureus* (MRSA) at Prince A/Rhmanidery hospital, Al-Jouf, Saudi Arabia. *Journal of Medical Genetics and Genomics*. 2011; 3(3) : 41-45.
27. Elhassan MM, Ozbak, HA, Hemeg HA, Elmekki MA and Ahmed LM. Absence of the *mecA* Gene in Methicillin Resistant *Staphylococcus aureus* Isolated from Different Clinical Specimens in Shendi City, Sudan. *BioMed Research International*, 2015; 1-5.
28. Sudigdoadi S. Analisis Tipe Staphylococcal Cassette Chromosome *mec* (SCC*mec*) Isolat Methicillin Resistant *Staphylococcus aureus* (MRSA). *MKB.* , 2010; 42 (4): 149 - 154.
29. Felten A, Grandry B, Lagrange PH, and Casin I. Evaluation of three techniques for detection of low-level Methicillin-Resistant *Staphylococcus aureus* (MRSA): a disk diffusion method with cefoxitin and moxalactam, the vitek 2 system, and the MRSA – screen latex agglutination test. *Journal of Clinical Microbiology*. 2002; 40 (8) : 2766 – 2771.
30. Sudigdoadi S. Analisis Tipe Staphylococcal Cassette Chromosome *mec* (SCC*mec*) Isolat IOP Conf. Series: Earth and Environmental Science 130 (2018) 012026 doi :10.1088/1755-1315/130/1/012026
31. Hiramatsu K. Vancomycin-resistant *Staphylococcus aureus*: a new model of antibiotic resistance. *Lancet Infect Dis*. 2001; 1(3):147-55.
32. El Ghodban A, Ghenghesh KS, Marialigeti K, Esahli H, Tawil A. PCR detection of toxic shock syndrome toxin of *staphylococcus aureus* from Tripoli, Libya. *J Med Microbiol*. 2006;55 (2):179–82. doi: 10.1099/jmm.0.46162-0. [PubMed: 16434710].
33. Qasim MT, Fenjan MN, Thijail HA. Molecular Identification of *Cystoisospora Belli* in Patients Infected With The Virus Human Immunodeficiency. *International Journal of Drug Delivery Technology*. 2022; 12(2):701-704.
34. Kord Z, Amini K. Determining geneses, TSST-1, can and antibiotic resistance in *staphylococcus aureus* strains isolated from clinical specimens. *J Ilam Univ Med Sci*. 2016;24 (3):31–9.
35. Arabestani MR, Rastiany S, Mousavi SF, Ghafel S, Alikhani MY. Identification of toxic shock syndrom and exfoliative toxin genes of *staphylococcus aureus* in carrier persons, resistant and susceptible methicillin. *Tehran Univ Med J*. 2015;73(8):554–60
36. Zhu, Yefei. “Staphylococcus Aureus Virulence Factors Synthesis Is Controlled by Central Metabolism.”2010.
37. Thomas, Damien Yann, Sophie Jarraud, Brigitte Lemercier, Gregoire Cozon, Klara Echasserieau, Jerome Etienne, Marie-Lise Gougeon, Gerard Lina, and François Vandenesch. “Staphylococcal Enterotoxin-like Toxins U2 and V, Two New Staphylococcal Superantigens Arising from Recombination within the Enterotoxin Gene Cluster.” *Infection and Immunity* . 2006; 74(8):4724–34.
38. Sharma, Hema, Debra Smith, Claire E. Turner, Laurence Game, Bruno Pichon, Russell Hope, Robert Hill, Angela Kearns, and Shiranee Sriskandan. “Clinical and Molecular Epidemiology of Staphylococcal Toxic Shock Syndrome in the United Kingdom.” *Emerging Infectious Diseases*. 2018; 24(2):258.
39. ROHMAH, Martina Kurnia, et al. Modulatory role of dietary curcumin and resveratrol on growth performance, serum immunity responses, mucus enzymes activity, antioxidant capacity and serum and mucus biochemicals in the common carp, *Cyprinus carpio* exposed to abamectin. *Fish & Shellfish Immunology*, 2022, 129: 221-230.
40. ARIF, Anam, et al. The functions and molecular mechanisms of Tribbles homolog 3 (TRIB3) implicated in the pathophysiology of cancer. *International Immunopharmacology*, 2023, 114: 109581.
41. MARGIANA, Ria, et al. Functions and therapeutic interventions of non-coding RNAs associated with TLR signaling pathway in atherosclerosis. *Cellular Signalling*, 2022, 100: 110471.
42. H. A. Al-Hchaimi, M. F. Alhamaidah, H. Alkhfaji, M. T. Qasim, A. H. Al-Nussairi and H. S. Abd-Alzahra, "Intraoperative Fluid Management for Major Neurosurgery: Narrative study," 2022 International Symposium on Multidisciplinary Studies and Innovative Technologies (ISMSIT), 2022, pp. 311-314, doi: 10.1109/ISMSIT56059.2022.9932659.
43. MOHAMMED, Zainab; QASIM, Maytham T. The Relationship between Insulin Resistance and Hypertension in Patient with Hypertensive. *HIV Nursing*, 2022, 22.2: 1659–1663-1659–1663.
44. LEI, Zimeng, et al. Detection of abemaciclib, an anti-breast cancer agent, using a new electrochemical DNA biosensor. *Frontiers in Chemistry*, 2022, 10.
45. BASHAR, Bashar S., et al. Application of novel Fe₃O₄/Zn-metal organic framework magnetic nanostructures as an antimicrobial agent and magnetic nanocatalyst in the synthesis of

- heterocyclic compounds. *Frontiers in Chemistry*, 2022, 10.
46. Shien, Lee Lian. "Comparative Genomic of Methicillin Resistant *Staphylococcus Aureus* Pr01 (MRSA PR01) and Methicillin Sensitive *Staphylococcus Aureus* SA D22901 (MSSA SAD22901) and Methicillin Resistant Derivatives of the Latter.", 2014.
 47. QASIM, M. T., et al. *Ovine Pasteurellosis Vaccine: Assessment of the Protective Antibody Titer and Recognition of the Prevailing Serotypes*. *Archives of Razi Institute*, 2022, 77.3: 1207-1210.
 48. Bocskay, Ildiko. "Methicillin-Resistant *Staphylococcus Aureus* Infections in the Eight Service Planning Areas of Los Angeles County." *Walden Dissertations and Doctoral Studies*, 2016.
 49. Zadeh, Firoozeh Abolhasani, et al. "Cytotoxicity evaluation of environmentally friendly synthesis Copper/Zinc bimetallic nanoparticles on MCF-7 cancer cells." *Rendiconti Lincei. Scienze Fisiche e Naturali* (2022): 1-7.